Illumina v. Molecular Loop: Genomics Patent Case Transferred to Delaware in Just 54 Days
Was möchten Sie als Nächstes tun?
Wählen Sie Ihren Weg entsprechend Ihren aktuellen Bedürfnissen:
📋 Fallzusammenfassung
| Fallbezeichnung | Illumina Inc. v. Molecular Loop Biosciences Inc. |
| Fallnummer | 1:24-cv-11501 (D. Mass.) & D. Del. successor docket |
| Gericht | U.S. District Court for the District of Massachusetts (Transferred to D. Del.) |
| Dauer | June 9, 2024 – August 2, 2024 54 days |
| Ergebnis | Procedural: Venue Transferred |
| Streitige Patente | |
| Beschuldigte Produkte | TruSight Oncology 500 ctDNA v2, VeriSeq NIPT Solution v2 assay |
Fallübersicht
Die Parteien
⚖️ Kläger
Global market leader in DNA sequencing and array-based technologies with an extensive IP portfolio in genomics and non-invasive prenatal testing (NIPT).
🛡️ Beklagter
Genomics company offering sequencing-based assay solutions, active in liquid biopsy and oncology sequencing markets.
Die streitigen Patente
This case involved five U.S. patents asserted by Illumina, Inc. and Verinata Health, Inc., covering critical technologies in next-generation sequencing (NGS), non-invasive prenatal testing (NIPT) methodology, and circulating tumor DNA (ctDNA) detection. These patents are registered with the U.S. Patent and Trademark Office (USPTO).
- • US11768200B2 (App. No. US17/339527) — Sequencing chemistry
- • US11840730B1 (App. No. US16/952764) — Sequencing chemistry
- • US11041851B2 (App. No. US14/854629) — NIPT methodology
- • US9163281B2 (App. No. US13/081660) — ctDNA detection
- • US11041852B2 (App. No. US17/149504) — NIPT methodology
Developing a new genomics assay?
Check if your NGS or liquid biopsy product might infringe these or related patents before launch.
Das Urteil und die rechtliche Analyse
Ergebnis
The Massachusetts District Court did not issue a merits ruling. The case was terminated in Massachusetts upon transfer to the District of Delaware pursuant to the parties’ Joint Motion to Transfer Venue. No damages were awarded, no injunctive relief was granted or denied, and no findings on validity or infringement were made at this stage.
The case remains active — now repositioned in Delaware for substantive adjudication.
Wichtige rechtliche Fragen
The sole dispositive action in Massachusetts was procedural: a consent-based venue transfer. The joint nature of the motion is strategically significant, indicating that both parties reached an agreement that Delaware was the more appropriate forum, avoiding a contested transfer motion that could have delayed proceedings and created early adversarial friction. Under 28 U.S.C. § 1404(a), courts may transfer cases for convenience of the parties and witnesses, or in the interest of justice.
Delaware’s District Court handles a disproportionate share of U.S. patent litigation due to its extensive IP expertise, well-developed local patent rules, and highly regarded docket management for complex multi-patent cases.
Freedom to Operate (FTO) Analysis in Genomics
This case highlights critical IP risks in NGS and liquid biopsy. Choose your next step:
📋 Die Auswirkungen dieses Falls verstehen
Informieren Sie sich über die spezifischen Risiken und Auswirkungen dieses Rechtsstreits.
- Alle zugehörigen Patente in diesem Technologiebereich anzeigen
- See which companies are most active in genomics patents
- Understand claim construction patterns specific to NGS
🔍 Das Risiko meines Produkts überprüfen
Führen Sie eine umfassende FTO-Analyse für Ihre eigene Technologie oder Ihr eigenes Produkt durch.
- Input your product description (e.g., NGS assay, NIPT solution)
- KI identifiziert potenziell blockierende Patente
- Erhalten Sie einen umsetzbaren Risikobewertungsbericht
Hochrisikogebiet
NGS and Liquid Biopsy Platforms
5 geltend gemachte Patente
In genomics sequencing technology
Strategische Design-Alternativen
Possible with FTO planning
✅ Wichtigste Erkenntnisse
Joint venue transfer motions are efficient tools for repositioning complex cases without adversarial delay.
Verwandte Rechtsprechung suchen →Portfolio assertions (5+ patents) are increasingly standard in genomics patent enforcement, maximizing leverage.
Portfolioanalyse-Tools entdecken →Delaware remains the preferred forum for multi-patent biotech disputes; counsel should anticipate this in initial venue analysis.
Understand Delaware’s patent rules →Häufig gestellte Fragen
Five U.S. patents were asserted: US11768200B2, US11840730B1, US11041851B2, US9163281B2, and US11041852B2 — covering NGS, NIPT, and ctDNA detection technologies.
Both parties jointly moved for transfer under 28 U.S.C. § 1404(a). The court granted the motion on August 2, 2024, citing the parties’ agreement that Delaware was the more appropriate forum.
It reinforces Delaware’s dominance as the preferred venue for complex biotech IP disputes and signals active enforcement of Illumina’s sequencing patent portfolio against commercial competitors in liquid biopsy and NIPT markets.
Ready to Strengthen Your Genomics IP Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision in life sciences.
Referenzen
- PACER: U.S. District Court for the District of Massachusetts — Case No. 1:24-cv-11501
- US-Patent- und Markenamt – Patentzentrum
- Cornell Legal Information Institute — 28 U.S.C. § 1404(a)
- PatSnap — IP Intelligence Solutions for Life Sciences
Dieser Artikel dient ausschließlich zu Informationszwecken und stellt keine Rechtsberatung dar. Alle Angaben zu den Fällen stammen aus öffentlich zugänglichen Gerichtsakten. Informationen zu den Funktionen der Plattform finden Sie auf PatSnap.